Lyell Immunopharma (LYEL) Return on Capital Employed (QoQ) (2021 - 2026)

Lyell Immunopharma (LYEL) Return on Capital Employed (QoQ) (2021 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Lyell Immunopharma 276.08 Mn 276.08 Mn -

Historic Data

Download Data
DateValue
Mar 31, 2026 -11.00
Dec 31, 2025 1,099.00
Sep 30, 2025 208.00
Jun 30, 2025 -1,003.00
Mar 31, 2025 -1,447.00
Dec 31, 2024 -3,558.00
Sep 30, 2024 -92.00
Jun 30, 2024 -28.00
Mar 31, 2024 -133.00
Dec 31, 2023 -754.00
Sep 30, 2023 -47.00
Jun 30, 2023 -485.00
Mar 31, 2023 -29.00
Dec 31, 2022 286.00
Sep 30, 2022 -286.00
Jun 30, 2022 121.00
Mar 31, 2022 -229.00
Dec 31, 2021 -134.00